Published in Am J Physiol Heart Circ Physiol on November 21, 2007
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest (2009) 4.39
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci U S A (2011) 2.80
Endogenous muscle atrophy F-box mediates pressure overload-induced cardiac hypertrophy through regulation of nuclear factor-kappaB. Circ Res (2011) 1.79
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation (2010) 1.49
Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ Res (2010) 1.34
Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol (2008) 1.23
Protein quality control and degradation in cardiomyocytes. J Mol Cell Cardiol (2008) 1.22
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res (2009) 1.16
A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am J Physiol Heart Circ Physiol (2008) 1.15
Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency. FASEB J (2008) 1.14
Proteasomal and lysosomal protein degradation and heart disease. J Mol Cell Cardiol (2013) 1.12
Proteasome inhibitors and cardiac cell growth. Cardiovasc Res (2009) 1.10
Regression of pressure-induced left ventricular hypertrophy is characterized by a distinct gene expression profile. J Thorac Cardiovasc Surg (2009) 1.09
The ubiquitin proteasome system in human cardiomyopathies and heart failure. Am J Physiol Heart Circ Physiol (2013) 0.99
The role of the proteasome in heart disease. Biochim Biophys Acta (2010) 0.99
Aging and dietary restriction effects on ubiquitination, sumoylation, and the proteasome in the heart. Mech Ageing Dev (2008) 0.93
The ubiquitin-proteasome system and cardiovascular disease. Prog Mol Biol Transl Sci (2012) 0.93
Understanding proteasome assembly and regulation: importance to cardiovascular medicine. Trends Cardiovasc Med (2008) 0.92
Autophagy and the ubiquitin-proteasome system in cardiac dysfunction. Panminerva Med (2010) 0.92
Protein quality control and metabolism: bidirectional control in the heart. Cell Metab (2015) 0.90
Recovery from decompensated heart failure is associated with a distinct, phase-dependent gene expression profile. J Surg Res (2012) 0.87
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies. Antioxid Redox Signal (2014) 0.85
Clarifying the cardiac proteasome paradox: protein quality control. Circ Res (2012) 0.81
Cardiomyocyte p65 nuclear factor-κB is necessary for compensatory adaptation to pressure overload. Circ Heart Fail (2014) 0.81
Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure. Circ Heart Fail (2013) 0.81
A modified murine model for the study of reverse cardiac remodelling. Exp Clin Cardiol (2013) 0.80
Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy. Front Physiol (2014) 0.78
Molecular- and organelle-based predictive paradigm underlying recovery by left ventricular assist device support. Circ Heart Fail (2014) 0.78
Breaking down protein degradation mechanisms in cardiac muscle. Trends Mol Med (2013) 0.78
Gambogic acid suppresses pressure overload cardiac hypertrophy in rats. Am J Cardiovasc Dis (2013) 0.77
Resuscitation of a dead cardiomyocyte. Heart Fail Rev (2015) 0.76
Cardiac specific expression of threonine 5 to alanine mutant sarcolipin results in structural remodeling and diastolic dysfunction. PLoS One (2015) 0.76
Inhibitory kappa-B kinase-β inhibition prevents adaptive left ventricular hypertrophy. J Surg Res (2012) 0.76
Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research. Mol Cell Biochem (2016) 0.76
The occurrence of left ventricular hypertrophy in normotensive individuals in a community setting in North-East Trinidad. Vasc Health Risk Manag (2011) 0.75
Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells. BMB Rep (2016) 0.75
Gambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-κB pathway. Am J Cardiovasc Dis (2013) 0.75
Ubiquitin and ubiquitin-like proteins in cardiac disease and protection. Curr Drug Targets (2015) 0.75
Proteostasis in cardiac health and disease. Nat Rev Cardiol (2017) 0.75
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest (2009) 4.39
A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature (2003) 4.18
Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A (2008) 4.00
NF-kappaB as a therapeutic target in cancer. Trends Mol Med (2002) 3.08
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol (2013) 2.92
Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev (2008) 2.89
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol (2002) 2.88
The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab (2007) 2.84
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev (2004) 2.51
Nitric oxide represses the Arabidopsis floral transition. Science (2004) 2.41
Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest (2007) 2.25
Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol (2005) 2.18
Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J Immunol (2008) 1.95
IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2007) 1.91
Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res (2009) 1.82
Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol (2004) 1.79
Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res (2010) 1.78
p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol Cell (2012) 1.76
Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg (2007) 1.75
A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle wasting. Am J Respir Crit Care Med (2012) 1.74
Tumor necrosis factor-alpha-induced caspase activation mediates endotoxin-related cardiac dysfunction. Crit Care Med (2005) 1.73
Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood (2006) 1.71
Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. Ann Thorac Surg (2009) 1.70
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res (2004) 1.65
Tear me down: role of calpain in the development of cardiac ventricular hypertrophy. Circ Res (2011) 1.61
IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem (2006) 1.57
Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy. Mol Cell Biol (2011) 1.55
The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta (2008) 1.53
Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res (2008) 1.51
Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A (2010) 1.48
LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell (2007) 1.47
Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care (2002) 1.44
Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death? J Heart Lung Transplant (2010) 1.44
Cystic fibrosis: newborn screening in America. MLO Med Lab Obs (2008) 1.42
Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev (2005) 1.42
Persistent low concentration of human chorionic gonadotropin in a nonpregnant woman. Clin Chem (2007) 1.39
NF-kappa B and I kappa B alpha are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-kappa B. J Biol Chem (2002) 1.37
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol (2002) 1.37
Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J Heart Lung Transplant (2009) 1.37
Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J (2005) 1.36
Myocardin inhibits cellular proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle progression. Proc Natl Acad Sci U S A (2008) 1.35
Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood (2004) 1.35
Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol (2002) 1.35
Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol (2010) 1.34
Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res (2007) 1.34
The bitter end: the ubiquitin-proteasome system and cardiac dysfunction. Circulation (2007) 1.34
NF-kappaB mediates inhibition of mesenchymal cell differentiation through a posttranscriptional gene silencing mechanism. Genes Dev (2003) 1.33
Muscle ring finger 1 mediates cardiac atrophy in vivo. Am J Physiol Heart Circ Physiol (2009) 1.33
Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood (2009) 1.29
Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem (2012) 1.28
IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway. PLoS One (2010) 1.22
Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J Immunol (2007) 1.22
IkappaB kinase alpha and p65/RelA contribute to optimal epidermal growth factor-induced c-fos gene expression independent of IkappaBalpha degradation. J Biol Chem (2004) 1.20
Myosin light chain phosphorylation is critical for adaptation to cardiac stress. Circulation (2012) 1.19
Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Res (2012) 1.19
Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail (2013) 1.19
The nuclear factor kappaB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res (2004) 1.19
Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res (2007) 1.19
Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol (2003) 1.19
Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res (2009) 1.18
Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation (2006) 1.17
Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli. Immunity (2010) 1.17
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res (2009) 1.16
PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem (2002) 1.15
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood (2012) 1.15
Diagnostic implications of C-reactive protein. Arch Surg (2003) 1.15
Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol (2008) 1.15
Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified? Circulation (2012) 1.14
The histone methyltransferase Set7/9 promotes myoblast differentiation and myofibril assembly. J Cell Biol (2011) 1.13
GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov (2013) 1.13
Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation (2012) 1.11
Regression of pressure-induced left ventricular hypertrophy is characterized by a distinct gene expression profile. J Thorac Cardiovasc Surg (2009) 1.09
Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med (2011) 1.09
Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2011) 1.07
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol (2003) 1.06
The ubiquitin ligase MuRF1 protects against cardiac ischemia/reperfusion injury by its proteasome-dependent degradation of phospho-c-Jun. Am J Pathol (2011) 1.06
NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo. Am J Pathol (2011) 1.05
The kinases MSK1 and MSK2 are required for epidermal growth factor-induced, but not tumor necrosis factor-induced, histone H3 Ser10 phosphorylation. J Biol Chem (2006) 1.05
Loss of microRNAs in neural crest leads to cardiovascular syndromes resembling human congenital heart defects. Arterioscler Thromb Vasc Biol (2010) 1.05
Back to your heart: ubiquitin proteasome system-regulated signal transduction. J Mol Cell Cardiol (2011) 1.05
Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol (2011) 1.04
Deletion of the NF-κB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. Blood (2013) 1.02
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res (2012) 1.01
Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS One (2009) 1.01
Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation. Cancer Res (2004) 1.01
NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin Cancer Res (2011) 1.00
Lipopolysaccharide is a cofactor for malondialdehyde-acetaldehyde adduct-mediated cytokine/chemokine release by rat sinusoidal liver endothelial and Kupffer cells. Alcohol Clin Exp Res (2004) 1.00